December 04, 2015

Amy Hamilton Joins FaegreBD as Co-Leader of Pharma/Biotech Practice

Amy Hamilton has joined Faegre Baker Daniels as counsel in the firm’s intellectual property group and co-leader of the pharma/biotech practice within the firm’s health and life sciences industry team.

Hamilton brings three decades of experience at Eli Lilly and Company, where she was Vice President and Deputy General Patent Counsel in the company’s patent division. In her role with FaegreBD, she will help pharmaceutical and other life sciences companies manage, protect and develop strategies for their patent portfolios. The Lilly teams she helped lead were responsible for the company’s U.S. and international patent procurement and maintenance activities; Hatch-Waxman, biotech and contract-based litigation; trade secret protection and litigation; trademark procurement and maintenance; European and other international oppositions and litigation; and client counseling on myriad intellectual property strategies.

A trained microbiologist, Hamilton’s understanding of the life sciences industry is vast. “Amy’s deep industry experience, at the intersection of intellectual property, commercial and contract law and patent strategy, will be invaluable to our growing list of life sciences clients,” said Pat Cross, leader of the firm’s health and life sciences industry team. “We’re excited to leverage Amy’s experience and strategic thinking for the benefit of our life sciences clients, and look forward to her leadership within our pharma/biotech practice.”

Hamilton received her bachelor’s degree in microbiology from Indiana University, a master’s degree in molecular biology from Vanderbilt University, and her J.D. from the Indiana University McKinney School of Law. She is admitted to the Indiana Bar, the U.S. Court of Appeals for the Federal Circuit and the U.S. District Court for the Southern District of Indiana.

Services and Industries

Faegre Baker Daniels 网站使用 Cookie 来提升您的浏览体验。